Globe Trotting
Roche concludes acquisition of spark therapeutics
Roche and Spark Therapeutics, Inc. have announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Spark Therapeutics, based in Philadelphia, Pennsylvania, is a fully integrated, commercial company, committed to discovering, developing, and delivering gene therapies for genetic diseases, including blindness, hemophilia, lysosomal storage disorders, and neurodegenerative diseases. Spark Therapeutics will continue to operate as an independent company within the Roche Group.